Clinical development involving rare diseases poses a unique set of medical, scientific, and operational challenges. PRA understands these challenges and the critical success factors necessary to develop drugs for rare disease patients. It’s not a cookie-cutter formula, but rather a nimble approach that embraces the flexibility, creativity, and innovation needed to succeed in this arena. In the last 5 years, we have managed over 170 Phase I-IV rare disease studies, across 11 different therapeutic areas, resulting in the successful marketing approval of 16 drugs.
We’ve supported more than 150 infectious disease studies, leading to the approval of 13 important marketed products.
RARE DISEASES NEWSLETTER Volume 12, February 2019
This year we are excited to be hosting PRA’s first annual World Rare Disease Day event on February 28th, 2019. The event will be held at the PRA…